Compugen drug effective vs. type I diabetes animal model

Compugen (CGEN) +4.8% premarket after announcing a study of its CGEN-15001 Fc fusion protein drug candidate demonstrated high effectiveness in an animal model of autoimmune type I diabetes.

The study suggests the drug turns off the autoimmune process and may potentially lead to restoration of immune tolerance and resolution of autoimmunity, arresting disease progression.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs